Posted by: fuadelhibri on: April 2, 2012
Originally posted on Gazette.net Fuad El-Hibri has started a financial consulting business. He’s started telecommunications businesses. But his most challenging venture has been the Rockville biotech he helped launch 14 years ago. Still, El-Hibri — CEO and board chairman of Emergent BioSolutions — says the challenges are worth it, because the rewards are so great from protecting [...]
Posted by: fuadelhibri on: September 30, 2011
ROCKVILLE, Md., Aug 17, 2011 – Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab andbendamustine for patients with relapsed indolent non-Hodgkin’s B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical(TM) protein therapeutic in development for the [...]
